Best-value biological medicines: Ustekinumab
The Medicines Management Programme (MMP) has identified best-value biological (BVB) medicines for medicinal products containing ustekinumab.
The MMP recommends the following as BVB medicines for ustekinumab:
- Imuldosa® (Accord Healthcare Ireland Limited)
- Otulfi® (Fresenius Kabi Ireland)
- Pyzchiva® (Sandoz Limited trading as Rowex)
- Wezenla® (Amgen Ireland Limited)
A copy of the MMP Evaluation Report is available in the Related Files section below.
Clinicians should give due consideration to prescribing Imuldosa®, Otulfi®, Pyzchiva® or Wezenla® when issuing a prescription for ustekinumab for the treatment of plaque psoriasis, psoriatic arthritis or Crohn’s disease.
The MMP recommends that:
- all new patients being initiated on ustekinumab for the treatment of plaque psoriasis, psoriatic arthritis or Crohn’s disease should be prescribed a BVB medicine
- patients currently established on ustekinumab for the treatment of plaque psoriasis, psoriatic arthritis or Crohn’s disease should be considered for switching to a BVB medicine at the earliest possible opportunity.
Resources to support prescribing of the BVB medicine are located in the Related Files section below:
- MMP Communication - BVB Medicines Ustekinumab 19 December 2025
- BVB Ustekinumab Questions & Answers for Healthcare Professionals
- BVB Reimbursement of Ustekinumab Q and A for Healthcare Professionals
- BVB Ustekinumab Patient Information
- BVB Product Information Sheet for Imuldosa®, Otulfi®, Pyzchiva® and Wezenla®
- BVB Ustekinumab Patient and Clinic Support Services.
For further information, please contact mmp@hse.ie.